The New Drug Application (NDA) for viloxazine hydrochloride (SPN-812; Supernus Pharmaceuticals), a serotonin norepinephrine modulating agent, has been submitted to the Food and Drug Administration (FDA) for the treatment of pediatric patients with attention deficit hyperactivity disorder (ADHD).
Prevention programs may improve long-term outcomes in children and adolescents by addressing pre-existing vulnerabilities that increase the risk for exposure to bullying.
The FDA has permitted for marketing the first medical device indicated for the treatment of attention deficit hyperactivity disorder ADHD.
Odds of both ASD and ADHD increased for later-born siblings of children with either diagnosis.
This research rejects any association between increased risk for ADHD and changes in children’s microbiota related to cesarean delivery or antibiotic use.
Significant increases in prevalence in subgroups by age, sex, race/ethnicity, income, geographic region.
Association holds after adjustment for unmeasured genetic, environmental factors
Diethylstilbestrol exposure during pregnancy is associated with multigenerational neurodevelopmental deficits in childhood, including ADHD.
Co-occurrence of attention-deficit/hyperactivity disorder is common in children with autism spectrum disorder.
A study of an investigational digital medicine achieves its primary efficacy end point in pediatric ADHD.
